Radiopharm Theranostics Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Riccardo Canevari
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 62 Lygon Street Carlton VIC Australia 3053
- IPO Date
- Dec 5, 2024
- CIK
- 0001949257
- Website
- radiopharmtheranostics.com
- Similar Companies
- Business
- Radiopharm Theranostics Limited (NASDAQ:RADX; ASX:RAD), a clinical-stage biopharmaceutical company, develops radiopharmaceutical products for diagnostic and therapeutic applications in oncology, targeting areas of high unmet medical need such as solid tumors including non-small cell lung cancer, breast cancer, brain metastases, pancreatic cancer and prostate cancer; its pipeline features therapeutic candidates RAD204 (PD-L1-targeted nanobody with Lutetium-177 for PD-L1-positive solid tumors in Phase 1), RAD202 (HER2-targeted nanobody with Lutetium-177 for HER2-positive solid tumors in Phase 1), and RV01 (B7-H3-targeted monoclonal antibody with Lutetium-177 for B7-H3-positive solid tumors in Phase 1/2a), alongside diagnostic agents RAD101 (short-chain fatty acid small molecule with Fluorine-18 for brain metastases in Phase 2b), RAD301 (alpha-v-beta-6 integrin peptide with Gallium-68 for pancreatic cancer in Phase 1), and preclinical programs RAD402 (KLK3-targeted monoclonal antibody with Terbium-161 for prostate cancer) and RAD302 (alpha-v-beta-6 therapeutic counterpart with Lutetium-177). Founded in 2021 and headquartered in Carlton, Australia, the company operates globally with clinical trials in the United States and Australia, leveraging platforms like Nano-mAbs, Pivalate and AVB6 Integrin derived from leading institutions. Recent developments include a strategic co-development partnership with Lantheus announced in December 2024 to advance radiopharmaceuticals in Australia, US FDA Fast Track Designation for RAD101, positive dose escalation for RAD204 to 60mCi, 50% enrollment in the RAD101 Phase 2b trial with topline data expected in first-half 2026, completion of a A$70 million placement in 2024, a NASDAQ listing in 2024, and initiation of its first Phase 2b trial in 2025.
Radiopharm Theranostics Reports Business Update
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study
Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX)
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Average Rating of “Buy” by Brokerages
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages
RAD Increases Ownership in Radiopharm Ventures to 87.5%
Why Is Radiopharm Theranostics Stock Rallying Over 140%?